Komori
Other Disclosures4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

(Correction) Partial correction to the notice titled "Approval Obtained for the Manufacture and Marketing of Droechiflex Combination Drug "Asuka""

The drug formulation name has been corrected from “Combination Product” to “Combination Tablet.” The correction applies to the title, body, summary title and marketing name.

Worth reading
21Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure17 August 2026

Notice of Obtaining Marketing Approval for ドロエチフレックス® Combination Product “Asuka”

Open the original document
Corrected on the same dayCorrected on the same day as the original document (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2026-08-17
Location of correction (where in the original document)

Title, body, summary title and marketing name

Before correction

Droechiflex Combination Tablets® “ASKA”

After correction

ドロエチフレックス® Combination Tablet “Asuka”

Changes“Combination Product” corrected to “Combination Tablet”
Reason for correction

Because certain information required correction

What was corrected and how
ItemDetails
Disclosure subject to correctionNotice of Obtaining Marketing Approval for ドロエチフレックス® Combination Product “Asuka”
Original disclosure date17 August 2026
Location of correctionTitle, body, summary title and marketing name
Details of correctionDroechiflex Combination Tablets® “ASKA” → ドロエチフレックス® Combination Tablet “Asuka”
Reason for correctionBecause certain information required correction
Items this document does not state (1)
Impact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The disclosure published on 17 August 2026 contained information requiring correction. No specific cause was stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Correction) Partial correction to the notice titled "Approval Obtained for the Manufacture and Marketing of Droechiflex Combination Drug "Asuka"" | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori